JW Therapeutics, a Shanghai-based clinical-stage biopharmaceutical company, has completed of a US$100 million series B round financing co-led by CPE and Mirae Asset. CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, and WuXi AppTec also participated in the round. This round of financing brings the total capital raised to over US$200 million.